Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02929823 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders
A Phase 2 study, sponsored by Senju Pharmaceutical Co..
- Completed
- Registry status
- Phase 2
- Development phase
- 130
- Enrollment target
NCT02929823 is a Phase 2 study that has completed, run by Senju Pharmaceutical Co.. The registered enrollment target is 130 participants.
The verdict
NCT02929823, a Phase 2 study, has completed, sponsored by Senju Pharmaceutical Co..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 130 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether SJP-0035 ophthalmic solution is effective in promoting corneal epithelial wound healing in conditions associated with corneal epithelial disorders.
Interventions
- DRUG High Dose SJP-0035 Ophthalmic Solution
- DRUG Low Dose SJP-0035 Ophthalmic Solution
- DRUG Vehicle of SJP-0035 Ophthalmic solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2016-09 |
| Est. Completion | 2017-05-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02929823
The ClinicalTrials.gov registry entry for NCT02929823 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Senju Pharmaceutical Co., which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which High Dose SJP-0035 Ophthalmic Solution is the first listed.
NCT02929823 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02929823 about?
NCT02929823 is a clinical study titled "Safety and Efficacy of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders". The purpose of this study is to determine whether SJP-0035 ophthalmic solution is effective in promoting corneal epithelial wound healing in conditions associated with corneal epithelial disorders.
What is the current status of trial NCT02929823?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2016-09. Estimated completion is 2017-05-03.
What interventions are being tested in trial NCT02929823?
The interventions under investigation include: High Dose SJP-0035 Ophthalmic Solution (DRUG), Low Dose SJP-0035 Ophthalmic Solution (DRUG), Vehicle of SJP-0035 Ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT02929823?
This trial is sponsored by Senju Pharmaceutical Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.